Vasodilation composition containing ergothioneine

MYPI2025004912A0Undetermined Publication Date: 2024-08-16SUNTORY HLDG LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004912
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-16
Filing Date
2024-02-13
Publication Date
2024-08-16

AI Technical Summary

Technical Problem

Current compositions do not effectively address the vasodilatory effects of ergothioneine or its influence on ATP-sensitive potassium channels, which are crucial for improving circulatory function and related conditions such as hypertension, stiff shoulders, and cerebral circulation.

Method used

A composition containing ergothioneine or its salt, specifically L-ergothioneine, which inhibits substrate binding to ATP-sensitive potassium channels, thereby dilating blood vessels and exerting a vasodilatory effect, is used as an oral food or drink to prevent or ameliorate conditions like hypertension and improve blood flow.

Benefits of technology

The ergothioneine-based composition safely and effectively lowers diastolic and systolic blood pressure, promoting blood circulation and alleviating conditions like hypertension, stiff shoulders, and decreased cerebral circulation by dilating blood vessels through ATP-sensitive potassium channels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025004912_DRAWING_001
    Figure PI2025004912_DRAWING_001
Patent Text Reader

Abstract

The present invention aims to provide a vasodilator composition. The present invention relates to a vasodilator composition containing ergothioneine or a salt thereof as an active ingredient. Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Vasodilatory composition containing ergothioneine

[0001] The present invention relates to a vasodilatory composition containing ergothioneine, etc.

[0002] In recent years, research and development of food ingredients with bioregulatory functions has been actively conducted to prevent lifestyle-related diseases. For example, circulatory function is an important function for maintaining a healthy body. It is believed that daily intake of foods that maintain or improve circulatory function can not only improve circulatory function but also improve related symptoms such as blood pressure, stiff shoulders, headaches, sensitivity to cold, and decreased cerebral circulation.

[0003] ATP-sensitive potassium (K ATP) channels close when the intracellular ATP concentration increases, and conversely, open when the ATP concentration decreases or the intracellular ADP concentration increases. To date, the presence of K ATP channels has been confirmed in various tissues, such as pancreatic islet β cells, cardiac muscle, skeletal muscle, smooth muscle, and central and peripheral nerve cells. Potassium channel openers (KCOs), developed as antihypertensive drugs, activate K ATP channels and are attracting attention as new targets for cardiovascular disease therapeutics (Non-Patent Document 1).

[0004] Ergothioneine is an amino acid found in mushrooms etc., and naturally exists in the L-form. Patent Document 1 discloses a blood vessel wall strengthening agent containing soy protein and / or ergothioneine as active ingredients, and describes that when subjects applied the blood vessel wall strengthening agent under their eyes, blood flow improved and dark circles under the eyes became lighter.

[0005] Japanese Patent Application Laid-Open No. 2022-006753

[0006] Folia Pharmacol. Jpn. 126, 311-316 (2005)

[0007] However, Patent Document 1 does not describe at all the vasodilatory action of ergothioneine or its effect on K ATP channels.

[0008] An object of the present invention is to provide a composition for dilating a blood vessel.

[0009] As a result of extensive research conducted by the present inventors to solve the above problems, they have found that L-ergothioneine or a salt thereof has a vasodilatory effect.

[0010] That is, the present invention relates to the following compositions for vasodilating, although not limited thereto: [1] A composition for vasodilating, comprising ergothioneine or a salt thereof as an active ingredient. [2] The composition according to [1] above, which is used for preventing or ameliorating hypertension. [3] The composition according to [1] or [2] above, which dilates blood vessels via ATP-sensitive potassium channels. [4] The composition according to any of [1] to [3] above, which is an oral composition. [5] The composition according to any of [1] to [4] above, which is a food or drink. [6] The composition according to any of [1] to [5] above, which is labeled with at least one function selected from the group consisting of "dilating blood vessels to maintain blood flow," "promoting blood circulation," "preventing or ameliorating hypertension," "preventing or ameliorating stiff shoulders," "preventing or ameliorating headache," "preventing or ameliorating sensitivity to cold," "preventing decreased cerebral circulation," and "improving cerebral circulation." [7] A method for vasodilating, which comprises administering ergothioneine or a salt thereof to a subject. [8] Use of ergothioneine or a salt thereof for dilating blood vessels.

[0011] According to the present invention, a composition for vasodilating can be provided.

[0012] Figure 1 is a graph evaluating the substrate binding inhibitory activity of L-ergothioneine on ATP-sensitive potassium channels. Figure 2 is a graph showing changes in diastolic blood pressure in the test food group and the control food group. Figure 3 is a graph showing changes in systolic blood pressure in the test food group and the control food group.

[0013] The vasodilatory composition of the present invention contains ergothioneine or a salt thereof as an active ingredient. Hereinafter, the vasodilatory composition of the present invention will also be referred to as the "composition of the present invention." Ergothioneine is a type of sulfur-containing amino acid. In the present invention, ergothioneine is preferably L-ergothioneine. The salt of ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and may be either an acidic salt or a basic salt. Examples of acidic salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.

[0014] Ergothioneine or a salt thereof is not limited in any way by its form, production method, etc. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from a natural product. L-ergothioneine is contained in large amounts in the Golden / Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), a mushroom of the Pleurotus genus in the family Pleurotus. L-ergothioneine is found in mushrooms such as white button mushrooms, crimini mushrooms, and portabella mushrooms (Agaricus bisporus), Grey Oyster Mushrooms (Pleurotus ostreatus), shiitake mushrooms (Lentinula edodes), Maitake mushrooms (Grifola frondosa), reishi mushrooms (Ganoderma lucidum), Yamabushitake mushrooms (Hericium erinaceus), Yanagimatsutake mushrooms (Agrocybe aegerita), and chanterelle mushrooms (Cantharella verruca). It is also contained in mushrooms such as mushrooms such as Pleurotus cibarius, porcini mushroom (scientific name: Boletus edulis), and morel mushroom (scientific name: Morchella esculenta). When obtaining L-ergothioneine from a natural product, it is preferably extracted from Pleurotus cornucopiae. Ergothioneine or a salt thereof can also be produced by microbial fermentation. Ergothioneine or a salt thereof may be isolated.

[0015] L-ergothioneine or a salt thereof is a compound that is contained in natural products and foods and beverages and has been consumed as a dietary ingredient. Therefore, from the viewpoint of safety, ergothioneine or a salt thereof is considered to pose few problems, even when taken over a long period of time. According to the present invention, a highly safe vasodilatory composition can be provided.

[0016] As shown in the Examples below, L-ergothioneine inhibited the binding of substrates to ATP-sensitive potassium (K ATP) channels. Furthermore, when L-ergothioneine was taken, diastolic blood pressure and systolic blood pressure decreased compared to when L-ergothioneine was not taken. It is known that when substrate binding to K ATP channels is inhibited, the K ATP channels open and blood vessels dilate. Therefore, ergothioneine dilates blood vessels via K ATP channels. Ergothioneine or a salt thereof can dilate blood vessels via K ATP channels. Ergothioneine or a salt thereof has the effect of lowering blood pressure by dilating blood vessels.

[0017] The composition of the present invention has a vasodilatory effect and is used to prevent or ameliorate conditions or diseases for which vasodilation is effective in preventing or ameliorating them. Preventing a condition or disease includes preventing the onset, delaying the onset, reducing the incidence, reducing the risk of onset, etc. Ameliorating a condition or disease includes recovering a subject from a condition or disease, alleviating the symptoms of a condition or disease, improving the symptoms of a condition or disease, delaying or preventing the progression of a condition or disease, etc. Recovery includes partial recovery.

[0018] Examples of conditions or diseases for which vasodilation is effective in preventing or ameliorating include high blood pressure, stiff shoulders, headache, sensitivity to cold, and decreased cerebral circulation. The vasodilatory effect is expected to prevent or ameliorate high blood pressure, stiff shoulders, headache, sensitivity to cold, and decreased cerebral circulation. In particular, the composition of the present invention is preferably used for preventing or ameliorating high blood pressure.

[0019] The composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition. Specific examples of oral compositions include foods and beverages, oral pharmaceuticals, quasi-drugs, feed, etc., and are preferably foods and beverages or oral pharmaceuticals, more preferably foods and beverages. The composition of the present invention may be a material or preparation to be incorporated into foods and beverages, pharmaceuticals, quasi-drugs, feed, etc.

[0020] The compositions of the present invention can be used for either therapeutic (medical) or non-therapeutic (non-medical) purposes, the latter being a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis.

[0021] The composition of the present invention may contain any additives and any components in addition to ergothioneine or a salt thereof, as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, etc. When the composition of the present invention is an oral composition, additives that can generally be used in oral compositions such as foods and beverages, pharmaceuticals, quasi-drugs, and feeds can be used.

[0022] When the composition of the present invention is used in the form of a food or drink, a pharmaceutical product, a quasi-drug, a feed, etc., the method for producing the composition is not particularly limited, and the composition can be produced by a general method. The form of the oral composition of the present invention is not particularly limited, and the composition may be in the form of a solid (powder, granules, tablet, etc.), a liquid, a paste, etc.

[0023] For example, when the composition of the present invention is made into a food or beverage, various foods and beverages can be prepared by blending ergothioneine or a salt thereof with ingredients that can be used in foods and beverages (e.g., food ingredients, food additives used as needed, etc.). The foods and beverages are not particularly limited, and examples include general foods and beverages, health foods, health supplements, health drinks, functional foods, foods for specified health uses, and foods and beverages for patients. The health foods, health supplements, functional foods, foods for specified health uses, etc. can be used in various dosage forms, such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, and liquid diets.

[0024] When the composition of the present invention is used as a pharmaceutical or quasi-drug, it can be formulated into various dosage forms by blending ergothioneine or a salt thereof with a pharmacologically acceptable carrier and, if necessary, additives. Such carriers, additives, etc. may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, etc. The pharmaceutical or quasi-drug may be administered orally or parenterally (transdermally, transmucosally, enterally, by injection, etc.). When the composition of the present invention is used as a pharmaceutical or quasi-drug, it is preferably an oral pharmaceutical or oral quasi-drug. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, etc. Dosage forms for parenteral administration include, for example, injections, drip infusions, ointments, lotions, patches, suppositories, nasal preparations, pulmonary preparations (inhalants), etc. The pharmaceutical product may be a pharmaceutical product for non-human animals.

[0025] When the composition of the present invention is used as a feed, ergothioneine or a salt thereof may be blended into the feed. Feed also includes feed additives. Examples of feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.

[0026] The subject to which the composition of the present invention is ingested or administered (which can also be referred to as the administration subject) is not particularly limited. It is preferably a human or a non-human mammal, and more preferably a human. In one embodiment, the administration subject includes a subject requiring or desiring vasodilation, or a subject requiring or desiring the prevention or amelioration of a condition or disease for which vasodilation is effective in preventing or ameliorating the condition. Such subjects include, for example, middle-aged and elderly people. In one embodiment, the composition of the present invention is suitably used as a vasodilatory composition for middle-aged and elderly people, or a composition for middle-aged and elderly people for the prevention or amelioration of a condition or disease for which vasodilation is effective in preventing or ameliorating the condition. Middle-aged and elderly people include elderly people. Middle-aged and elderly people may be, for example, people aged 40 or older. In one embodiment, among middle-aged and elderly people, elderly people are preferred as the subject. Elderly people may be, for example, people aged 60 or older or 65 or older. The administration subject may be a healthy individual. The composition of the present invention can also be used in healthy individuals for the purpose of, for example, vasodilation, or the prevention or amelioration of a condition or disease for which vasodilation is effective in preventing or ameliorating the condition or disease. In the present invention, particularly preferred subjects are healthy humans aged 60 years or older and younger than 75 years, and most preferred subjects are healthy humans aged 60 years or older and younger than 65 years.

[0027] The content of ergothioneine or a salt thereof in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of ergothioneine or a salt thereof in the composition of the present invention, calculated as ergothioneine, is, for example, preferably 0.0001% by weight or more, more preferably 0.001% by weight or more, and preferably 90% by weight or less, more preferably 50% by weight or less. In one aspect, the content of ergothioneine or a salt thereof in the composition of the present invention, calculated as ergothioneine, is preferably 0.0001 to 90% by weight, more preferably 0.001 to 50% by weight. The content of ergothioneine or a salt thereof can be measured by high-performance liquid chromatography (HPLC).

[0028] In this specification, the expression "ergothioneine equivalent amount" or similar expressions means the amount of ergothioneine, and in the case of a salt of ergothioneine, means the value obtained by multiplying the number of moles of the salt by the molecular weight of ergothioneine.

[0029] The composition of the present invention can be ingested or administered by an appropriate method depending on its form. In one embodiment, the composition of the present invention is preferably ingested orally (administered orally). The dosage (also referred to as intake amount) of the composition of the present invention is not particularly limited, and may be an amount that provides a vasodilatory effect, and may be appropriately determined depending on the dosage form, administration method, subject weight, etc.

[0030] In one embodiment, when the composition of the present invention is orally ingested or administered to a human (adult), the dosage is preferably 2 mg or more, more preferably 5 mg or more, even more preferably 7 mg or more, and preferably 50 mg or less, more preferably 25 mg or less, and even more preferably 20 mg or less per day, in terms of ergothioneine or a salt thereof (ergothioneine equivalent). In one embodiment, the dosage of the composition of the present invention is preferably 2 to 50 mg, more preferably 5 to 25 mg, even more preferably 5 to 20 mg, and even more preferably 7 to 20 mg per day, in terms of ergothioneine or a salt thereof (ergothioneine equivalent). It is preferable that the above amount be ingested or administered once or more times a day, for example, once a day or in divided doses (e.g., 2 to 3 times a day). In one embodiment, the above amount of ergothioneine or a salt thereof is orally ingested or administered to a human. The above dosage may be per 60 kg of body weight. In one embodiment, the composition of the present invention can be used to cause or administer to a human, for example, the above-mentioned amount of ergothioneine or a salt thereof per 60 kg of body weight per day.

[0031] The content of ergothioneine or a salt thereof in the composition of the present invention is preferably 2 to 50 mg, more preferably 5 to 25 mg, even more preferably 5 to 20 mg, and particularly preferably 7 to 20 mg, of ergothioneine per daily intake for an adult.

[0032] The composition of the present invention may be labeled with, for example, a function of dilating blood vessels; or a function exerted by vasodilation. The composition of the present invention may be labeled with at least one function selected from the group consisting of "dilating blood vessels to maintain blood flow," "promoting blood circulation," "preventing or improving high blood pressure," "preventing or improving stiff shoulders," "preventing or improving headaches," "preventing or improving sensitivity to cold," "preventing decreased cerebral circulation," and "improving cerebral circulation." In one aspect, the composition of the present invention is preferably a food or beverage labeled with the above-mentioned label. The above-mentioned label may also be a label indicating that the composition is used to obtain the above-mentioned function. The above-mentioned label may be attached to the composition itself, or to the container or packaging of the composition.

[0033] As described above, L-ergothioneine inhibits the binding of substrates to K ATP channels. Therefore, ergothioneine or a salt thereof can also be used as an active ingredient for inhibiting substrate binding to K ATP channels. The composition of the present invention may also be used as a substrate binding inhibitor for K ATP channels. A substrate binding inhibitor for K ATP channels containing ergothioneine or a salt thereof as an active ingredient also constitutes one aspect of the present invention.

[0034] The present invention also encompasses the following method: a method for vasodilation, which comprises administering ergothioneine or a salt thereof to a subject. The method may be a therapeutic method or a non-therapeutic method.

[0035] The present invention also encompasses the following use: Use of ergothioneine or a salt thereof for dilating blood vessels. The use may be therapeutic or non-therapeutic. By administering ergothioneine or a salt thereof to a subject, blood vessels can be dilated.

[0036] In the above-mentioned methods and uses, the preferred embodiment of ergothioneine or a salt thereof is the same as that of the composition of the present invention described above. As ergothioneine or a salt thereof, one type of ergothioneine or a salt thereof may be used, or two or more types may be used. In the above-mentioned methods and uses, it is preferable to administer (ingest) ergothioneine or a salt thereof to a subject at least once a day, for example, once to several times (e.g., two to three times) a day. In the above-mentioned methods and uses, it is preferable to orally administer (ingest) ergothioneine or a salt thereof. The above-mentioned uses are preferably used in humans or non-human mammals, more preferably in humans.

[0037] In the above-mentioned methods and uses, ergothioneine or a salt thereof may be used in an amount sufficient to achieve the desired effect (which may also be referred to as an effective amount). The preferred dosage and administration targets of ergothioneine or a salt thereof are the same as those of the above-mentioned composition of the present invention. Ergothioneine or a salt thereof may be administered directly or as a composition containing it. For example, the above-mentioned composition of the present invention may be used.

[0038] The present invention also encompasses the use of ergothioneine or a salt thereof for producing a composition for vasodilating.The present invention also encompasses the use of ergothioneine or a salt thereof for producing a composition for preventing or ameliorating hypertension.The present invention also encompasses ergothioneine or a salt thereof for use in the prevention or amelioration of hypertension.

[0039] In this specification, a numerical range expressed by a lower limit and an upper limit, i.e., "lower limit to upper limit," includes the lower limit and the upper limit. For example, a range expressed by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper limit and the lower limit may be any combination of ranges.

[0040] The present invention will be described in more detail below with reference to examples, but the scope of the present invention is not limited to these examples.

[0041] Example 1 (Evaluation of substrate binding inhibitory activity on ATP-sensitive potassium channels) To evaluate the molecular target on which L-ergothioneine acts, an in vitro assay was carried out on the ATP-sensitive potassium (KATP) channel. The in vitro assay was carried out as a contract test at Eurofins Panlabs. The test was carried out by the following method.

[0042] 400 μg of membrane fraction from rat cerebral cortex (containing K ATP channels, manufactured by Eurofins Cerep) was diluted with 0.1 nM [ 3 The cells were incubated with [H] glibenclamide and L-ergothioneine (L-ergothioneine concentration: 100 μM or 1000 μM) at 22°C for 60 minutes. Glibenclamide is a K ATP channel inhibitor. Nonspecific binding was determined in the presence of 1 μM glibenclamide (no L-ergothioneine). When glibenclamide was present in excess, [ 3 Since [H]glibenclamide is no longer able to bind to the K ATP channel, the radioactivity detected there is nonspecific binding. The membrane fraction was filtered and washed, and the substrate binding inhibitory activity of L-ergothioneine was evaluated using radioactivity as an indicator. [H]glibenclamide bound to the K ATP channel 3 The higher the amount of [H]glibenclamide, the stronger the radioactivity of the membrane fraction.

[0043] FIG. 1 is a graph evaluating the substrate binding inhibitory activity of L-ergothioneine on ATP-sensitive potassium channels. The concentration (μM) on the horizontal axis represents the concentration of L-ergothioneine. The substrate binding inhibitory activity (%) on K ATP channels was determined by the following procedure. The radioactivity of the membrane fraction in the reaction solution without L-ergothioneine (control) was set to 100%, and the relative activity (%) of the membrane fraction in the reaction solution containing L-ergothioneine (100 μM or 1000 μM) relative to the control was calculated from the radioactivity of the membrane fraction. When L-ergothioneine inhibits the binding of glibenclamide to K ATP channels, the radioactivity of the membrane fraction is weakened. The substrate binding inhibitory activity (%) on K ATP channels was then calculated by subtracting the relative activity (%) of the membrane fraction in the control (100%).

[0044] L-ergothioneine exhibited inhibitory activity against the binding of its substrate, glibenclamide, to K ATP channels. It is known that opening of K ATP channels causes vasodilation, and it is presumed that L-ergothioneine exerts vasodilatory effects via K ATP channels.

[0045] Example 2 (Evaluation of blood pressure in humans) For the purpose of evaluating the effect of an ergothioneine-containing supplement on blood pressure in humans, a placebo-controlled, randomized, double-blind, parallel-group comparative study was conducted in healthy men and women aged 60 to 65 years (9 in the test food group, 10 in the control food group, a total of 19 people) in which they took a capsule containing 8 mg of ergothioneine (test food) or a capsule not containing ergothioneine (control food) once a day for 12 weeks.

[0046] First, the subjects' blood pressure was assessed before the start of the study (before starting to take the test food or control food). Furthermore, after 12 weeks of taking the test food or control food, the subjects' blood pressure was measured again (12-week examination). Blood pressure was generally measured on the upper arm opposite the dominant arm. Measurements were taken three times in a seated position after at least 10 minutes of rest after arriving at the clinic, and the median of the three measurements was recorded as the measurement on that day of evaluation. Under the supervision of a physician, a nurse or laboratory technician measured blood pressure using a medical electronic blood pressure monitor, AVE-1500 Pasesa (Shisei Datum Co., Ltd.).

[0047] (Foods for evaluation) Two types of foods were used for evaluation, which were indistinguishable in appearance, flavor, etc. Test food: Capsules containing the test substance (8 mg of L-ergothioneine) Control food: Capsules not containing the test substance In addition to the test substance, the ingredients of each food for evaluation include dextrin, calcium stearate, and hydroxypropyl methylcellulose. The control food was manufactured using the same ingredients as the test foods, except that it did not contain the test substance (L-ergothioneine).

[0048] The average blood pressure (mmHg) of the nine subjects in the test food group was used as the blood pressure of the test food group. The average blood pressure (mmHg) of the ten subjects in the control food group was used as the blood pressure of the control food group. In addition, for each group, the change in blood pressure (Δ blood pressure (mmHg)) was calculated by subtracting the blood pressure at the pre-study examination from the blood pressure at the 12-week examination. The change in blood pressure (Δ blood pressure (mmHg)) at the pre-study examination was set to 0. Two blood pressures, diastolic blood pressure and systolic blood pressure, were measured, and the change in each blood pressure, Δ diastolic blood pressure (mmHg) and Δ systolic blood pressure (mmHg), was calculated.

[0049] Figure 2 is a graph showing changes in diastolic blood pressure in the test food group and the control food group. A two-sample t-test (**: p<0.01 vs. the control food group) was used to test for significance between the groups. As a result, diastolic blood pressure was significantly reduced in the test food group. In Figure 2, black squares (■) represent the test food group, and white squares (□) represent the control food group. "0W" on the horizontal axis represents the test before the start of the study, and "12W" represents the test at week 12.

[0050] Figure 3 is a graph showing changes in systolic blood pressure in the test food group and the control food group. A two-sample t-test (**: p<0.01 vs. the control food group) was used to test for significance between groups. As a result, the rise in systolic blood pressure was more suppressed in the test food group than in the control food group. In Figure 3, black squares (■) represent the test food group, and white squares (□) represent the control food group. "0W" on the horizontal axis represents the test before the start of the study, and "12W" represents the test at week 12.

[0051] From the results of Examples 1 and 2, it is presumed that L-ergothioneine dilates blood vessels via K ATP channels and exhibits a blood pressure improving effect (hypertension prevention or improvement effect).

Claims

1. A composition for dilating blood vessels, comprising ergothioneine or a salt thereof as an active ingredient.

2. The composition according to claim 1, which is used for the prevention or amelioration of hypertension.

3. The composition described in claim 1 or 2, which dilates blood vessels via ATP-sensitive potassium channels.

4. The composition according to claim 1 or 2, which is an oral composition.

5. The composition according to claim 4, which is a food or drink.

6. The composition according to claim 1 or 2, which is labeled with at least one function selected from the group consisting of "dilates blood vessels to maintain blood flow", "promotes blood circulation", "prevents or improves high blood pressure", "prevents or improves stiff shoulders", "prevents or improves headaches", "prevents or improves poor circulation", "prevents reduced cerebral circulation" and "improves cerebral circulation".

7. A method for dilating blood vessels, comprising administering ergothioneine or a salt thereof to a subject.

8. Use of ergothioneine or a salt thereof for dilating blood vessels.